Depending on their mechanism of action, anticonvulsant drugs in clinical use may be divided into three groups: those drugs which facilitate ~-aminobutryic acid (GABA)ergic neurotransmission; those which block neuronal ion channels; and those whose mechanism of action is unresolved. The compounds acting on GABAergic systems may be further subdivided into those which modulate transmission through chloride channels, e.g. the barbiturates and the benzodiazepines; those compounds, in particular vigabatrin, which reduce the degradation of GABA by blocking GABA transaminase; and those which inhibit the re-uptake of GABA into the presynaptic terminal.
INTRODUCTION
In spite of a considerable research effort, the neurochemical irregularities underlying epilepsy are still not clearly understood. Uncontrolled electrical activity in the central nervous system may occur, either through a reduction in inhibitory neurotransmission or, conversely, through an increase in excitatory transmission. Changes in ionic conductances through neuronal membranes may underlie these abnormalities.
The major groupings of antiepileptic drugs can be defined as:
1. those which facilitate ~/-aminobutyric acid (GABA) transmission by various mechanisms; 2. those which block voltage-gated ion channels and thus reduce excitatory transmission; 3. those whose mechanism of action is still open to debate.
DRUGS ACTING ON GABAERGIC MECHANISMS
GABA is the major inhibitory transmitter throughout the neuroaxis and functions as the transmitter in both long axonal tracts and, perhaps more importantly in relation to epilepsy, is the transmitter of many interneurones. The function of these cells is to regulate the electrical activity in relatively small areas of neuropile and consequently the output of that area. For example, the vast majority of interneurones in the cerebral cortex are GABAergic and play an important part in controlling glutamate-mediated excitatory activity within the cortex, as well as excitatory output from the cortex. There are two subtypes of GABA receptors, designated GABAA and GABAB. GABAA receptors (which are bicuculline-sensitive) are located predominantly on postsynaptic membranes and are involved in fast neurotransmission; it is the interaction with these receptors that accounts for the action of both the benzodiazepines and the barbiturates. The GABAA receptor is part of the transmitter-gated channel which consists of five membrane-spanning subunits that form the pore through which chloride ions enter the postsynaptic neurone following GABAA receptor occupation. Each of the five subunits in turn consists of four distinct transmembrane-spanning domains. These subunits, which form the ionophore, have been designated ~, ~, ~, 8 and p, and each, with the exception of 8, have multiple isoforms. As a result of amino acid sequencing, there are six ~ subunits (al-a6), four 13 subunits (~1-~4), three ~ subunits (~-~3), a single ~ subunit, as well as two p subunits (pl-p2), with the latter appearing to be localized in the retina (see Enna for a review) 1. The presence of these many isoforms, and consequently of different pentameric combinations of subunits, raises the possibility of many different types of GABAA receptors with varying physiological characteristics. At present it is known, following co-expression of the various subunits in Xenopus oocytes, that and 13 subunits must be combined with a ~2 or ~3 in order to obtain a normal response to benzodiazepines, while substitution with a subunit removes any sensitivity.
The action of the benzodiazepines is described as allosteric modulation, because these drugs have no intrinsic activity at the GABAA receptor, both drug and transmitter having to be present simultaneously in order to facilitate neurotransmission. The resulting effect is an increased frequency of opening of chloride channels. In the case of phenobarbitone there is a prolongation in the open time of the channel. The resulting influx of chloride leads to hyperpolarization of the postsynaptic neurone and consequently a decrease in neuronal firing rate.
It must also be pointed out that a 2,3-benzodiazepine molecule (GYKI 52466), which has anticonvulsant properties, has been shown to non-competitively block the AMPA (L-alphaamino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid)/kainate subtype of glutamate receptor2; phenobarbitone has also been reported to be an antagonist at this receptor 3.
The mechanism of action of vigabatrin is also through a modification of GABAergic transmission. Following the release of GABA from a presynaptic terminal, some 70-80% of the transmitter is taken back into the neurone by a specific sodium/chloride voltagedependent re-uptake system. However, some of the released GABA is metabolized to succinic semialdehyde by GABA-transaminase and this also occurs to a small proportion of the GABA which is taken up into the terminal. Vigabatrin, by blocking GABA-transaminase 4, increases both synaptic and terminal GABA levels, thus leading to a potentiation of GABAergic-induced inhibition.
A further group of drugs with the potential to facilitate GABAergic transmission is that which inhibits the re-uptake of GABA. The prototypic compound in this group was nipecotic acid which was shown to be an effective re-uptake inhibitor in vitro. However, when given in vivo it did not cross the blood-brain barrier. Currently undergoing clinical trials, a derivative of nipecotic acid, tiagabine, has been shown to block the re-uptake of GABA 5 and to be active in vivo. GABAB receptors, which are bicuculline insensitive, are found both pre-and postsynaptically and are linked to guanosine triphosphate (GTP) binding proteins. Depending on the cellular location of these receptors, activation can lead to various physiological effects. GABAB receptors (autoreceptors) located on presynaptic GABAergic terminals are involved in the regulation of GABA release 6. Stimulation of these receptors leads to a decrease in GABA release, either through the opening of potassium channels or by inhibiting calcium entry into the terminal. Either (or both) mechanisms would lead to a reduction in exocytosis. Antagonists at GABAB autoreceptors would have potential anticonvulsant activity.
DRUGS ACTING ON VOLTAGE-OPERATED ION CHANNELS
Voltage-operated sodium and calcium ion channels in neuronal membranes are modified by antiepileptic drugs in current clinical usage. An inhibitory action at either, or both, of these channels has a marked effect of neuronal activity.
The anticonvulsant action of phenytoin is considered to be via a membrane-potentialdependent blockade of sodium channels. However, such a general reduction in sodiummediated transmission in a tetrodotoxin (TTX)-like manner is difficult to reconcile with a selective action of the drug on seizures. Phenytoin is far more effective in reducing sodium currents during high-frequency repetitive stimulation (neuronal conditions which are present during a seizure) than during normal brain activity which occurs at lower frequencies 7. The diversity of voltage-operated potassium and calcium channels has been recognized for a number of years. However, it is only recently that different voltage-operated sodium channels have been described (see Mandel for a review) s. These channels have been shown to have varying pharmacological and functional characteristics. Perhaps the most important functional difference in these channels is their inactivation kinetics in that some which are sensitive to TTX are slowly inactivating and these may thus play a vital role in sustained firing, as seen during a seizure. A specific action of phenytoin on a subtype of sodium channel could account for its pharmacological action.
Phenytoin has also been shown to affect extacellular Ca 2+ concentration by blocking the potassium-stimulated uptake of Ca 2+ into brain slices 9. During a seizure l°, or even before the initiation of a seizure 1~, the extracellular concentration of potassium increases markedly, resulting in depolarization of the neurones in that region. This depolarization leads to a decrease in extracellular calcium concentration as voltage-operated calcium channels open and calcium goes down its concentration gradient into the neurone. The increased interneuronal calcium concentration would then lead to exocytosis and enhanced excitatory neurotransmission; phenytoin, by blocking the entry of calcium, would reduce this excitation. However, an action of phenytoin on sodium channels could also account for these changes in the extracellular concentrations of calcium and potassium.
Lamotrigine ~2 and carbamazepine 13 have both been shown to have similar actions to phenytoin in that they are able to decrease sustained repetitive high-frequency stimulation of neuronal preparations. This action of both compounds may again be explained by an effect on voltage-operated sodium channels. Lamotrigine has also been shown to decrease the release of veratridine-stimulated glutamate from rat cortical slices, but was without effect on potassium-stimulated release 14. These results with lamotrigine again point to an action on voltage-operated sodium channels in that veratridine opens these channels. The reduction in the release of the major excitatory neurotransmitter in the central nervous system might account for the anticonvulsant action of lamotrigine, but it does appear contradictory in that TTX also blocks veratridineinduced glutamate release ~5, but obviously has no anticonvulsant properties.
Carbamazepine, as well as being an anticonvulsant, is used in bipolar illness and in the treatment of trigeminal neuralgia. As stated above, this drug also blocks sustained repetitive firing through an inhibitory action on sodium channels 13 and also facilitates potass-269 ium efflux. Either of these mechanisms could account for its antiepileptic action. However, two recent papers have shown that carbamazepine blocks the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor in cultured spinal cord neurones 16 and in cortical wedges prepared from genetically epilepsy-prone DBA/ 2 mice 17. In this latter study, concentrations of 0,5--10ftM carbamazepine reduced NMDAevoked depolarizations but concentrations above 50pM potentiated the depolarizations. This inhibitory action of carbamazepine on NMDA receptors could contribute to its anticonvulsant action (see later).
The final drug in this group of antagonists at voltage-operated ion channels is ethosuximide. It is well documented that ethosuximide reduces low-threshold calcium currents (Tcurrent) in thalamic preparations at therapeutic concentrations18. Thalamocortical neurones have been shown to have a spontaneous oscillatory activity of low frequency (approximately 3 Hz) and these pacemaker oscillations involve T-currents. These oscillatory currents are considered to play an important role in the generation of 3Hz spike-wave rhythms characteristic of absence epilepsy. The action of ethosuximide in reducing these T-currents probably explains its therapeutic action. Recent evidence on the role of GABAB receptors in the thalamus have shown that activation of these receptors produces hyperpolarization which promotes T-currents and enhances seizure frequency in animal models, while GABAB receptor antagonists decreased the incidence of seizures ~9. These results might explain why absence seizures are aggravated by those drugs which facilitate GABAergic neurotransmission.
DRUGS WHOSE MECHANISM OF ACTION IS UNRESOLVED
Although sodium valproate has been in clinical use for the treatment of a wide spectrum of seizure types for many years, its mechanism of action is still not fully understood. Early work suggested that valproate increased GABA levels presynaptically rather than acting through a facilitatory action on postsynaptic receptor mechanisms. The elevation of GABA concentrations could be accounted for by valproate inhibiting the enzymes involved in GABA degradation (GABA transaminase and succinic semialdehyde); however, concen-trations needed for such an action are much higher than those achieved clinically 2° and valproate is far less effective in this respect than is vigabatrin. Valproate has also been shown to increase GABA synthesis through stimulation of glutamic acid decarboxylase.
Valproate also decreases the effect of highfrequency repetitive firing of sodum-dependent action potentials in a use-and voltagedependent manner. Howver, 2-en-valproate, a metabolite of valproate, which has equivalent anticonvulsant properties to the parent compound in some animal models of epilsepy, has no effect on high-frequency repetitive firing of sodium-dependent action potentials 23. This latter observation raises doubts about the blockage of the sodium channel hypothesis. Another possible mechanism of action, especially as valproate is effective in absence seizures, is an inhibition of low-threshold Tcurrents, as is the case with ethosuximide. However, Coulter et al is found no effect on this current in thalamic neurones, whereas Kelly et a121 reported that valproate reduced T-current in nodose ganglion neurones. Sodium valproate has also been shown to activate a potassium conductance in rat hippocampal slices and such an action would lead to an efflux of potassium and subsequent hyperpolarization 22. It is probable that the reason why valproate has such a wide spectrum of anticonvulsant activity is due to a combination of mechanisms of action, its effect on GABAergic systems being augmented by possible sodium and T-current channel blockade (see Loscher for a recent review23).
Gabapentin, which has recently been introduced, has been shown to be effective in partial and generalized epilepsy. It was originally synthesized as a lipophilic analogue of GABA which would cross the blood-brain barrier. However, gabapentin does not possess high affinity for either GABAA or GABAB receptors. Initial studies suggested an antagonistic effect at the glycine modulatory site on the NMDA receptor complex (see below) in that D-serine (an agonist at this site) reversed the anticonvulsant action of gabapentin on tonic seizures in mice. However, binding studies demonstrated that gabapentin did not displace [3H] glycine or [3H]MK801 binding to brain membranes. A recent paper 24 compared the distribution of NMDA and gabapentin binding sites and showed that, while qualitatively there was close similarity between the two sites, quantitatively there were marked differences. Gabapentin has also been shown to bind to a novel high-affinity site in the central nervous system and to be displaced by the anticonvulsant 3-isobutyl GABA. There is evidence that this site may be linked to the transporter for large neutral L-amino acids such as L-methionine, Lleucine and L-isoleucine. These amino acids also potently displace gabapentin from its binding site 25. The significance of this finding and its possible relationship to an anticonvulsant action is unknown. In addition, recent work has shown that gabapentin does not have any effect on sodium or calcium voltagedependent channels or on GABA, glycine or glutamate (both NMDA and non-NMDA) receptors 26.
NMDA receptors play an important role in the mechanisms underlying epilepsy. The NMDA receptor-operated complex consists of an ion channel that allows an influx of calcium and to a lesser extent sodium and an efflux of potassium..As well as the channel, there are a number of binding sites on this complex where antagonism could have potential anticonvulsant properties.
Felbamate has been shown to have anticonvulsant properties against NMDA-induced convulsions in mice and also to inhibit binding of [3H] 5,7 dichloro:kynurenic acid at the glycine site on the NMDA receptor 27. The glycine site positively modulates NMDA receptor activation and antagonists at this site show anticonvulsant properties. Such an action could account for the anticonvulsant effects of felbamate.
Another compound undergoing clinical trials is remacemide whose activity probably resides in its desglycine metabolite. Remacemide is effective in inhibiting the effects of maximal electroshock in rats and NMDA-induced seizures in mice. In binding studies 2s the parent compound was reported not to bind to glutamate, GABAA, adenosine A1, benzodiazepine or NMDA receptors (at either the glycine or ion channel sites). However, further work showed that the desglycinated metabolite displaced MK801 binding from rat synaptosomal membranes. An antagonistic action of remacemide desglycine at a site(s) on the NMDA receptoroperated channel is probable.
In conclusion, the mechanism of action of the long-established anticonvulsant drugs on postsynaptic GABA receptors (benzodiazepines and phenobarbit0ne), or through inl~ibitory actions on voltage-sensitive ion cha~nels (voltageoperated sodium channels for pl~enytoin, lamo-trigine, and carbamazepine; voltage-operated calcium channels for ethosuximide) are well defined. The mode of action of sodium valproate is still open to debate, but it might well be that it has many actions which all contribute in some way to its wide spectrum of anticonvulsant activity. Much further work is needed to define the mechanisms of action of gabapentin, felbamate and remacemide.
